Boditech Med

• Showcased point-of-care solutions for latent tuberculosis and infection differentiation using the AFIAS platform
• Introduced 'ichroma 50 Plus,' an automated high-throughput device for latent tuberculosis diagnosis
• Aiming to expand partnerships and accelerate sales growth in the European market

Boditech Med, a leader in point-of-care diagnostics, announced that it unveiled its latest infectious disease diagnostic platforms at ESCMID Global 2025, held in Austria.

Organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), ESCMID Global is the world’s largest academic event dedicated to infectious diseases and clinical microbiology, attracting over 15,000 professionals from around 100 countries to share the latest research and technological advancements.

At the event, Boditech Med presented a range of point-of-care solutions targeting:

• Sepsis and severe infections
• Antimicrobial resistance (AMR)
• Tuberculosis
• Gastrointestinal health
• Tropical and global infectious diseases

Among the highlights were the AFIAS IGRA-TB for latent tuberculosis diagnosis and AFIAS MxA/CRP for viral-bacterial infection differentiation. These products drew strong interest for their rapid turnaround time, simple procedures, and high clinical utility.

AFIAS IGRA-TB is a rapid test kit that quantifies interferon-gamma to determine latent tuberculosis infection in just 15 minutes, dramatically reducing the complexity and labor-intensiveness associated with traditional IGRA testing. Its intuitive workflow makes it an ideal solution for field-focused global health programs.

Also launched at the event, the ichroma 50 Plus is a high-throughput device that fully automates the latent tuberculosis diagnostic process. Users can simply load the samples, and the device's system handles all subsequent steps automatically, significantly shortening testing time and offering a seamless, efficient diagnostic environment.

Meanwhile, AFIAS MxA/CRP is a next-generation infectious disease differentiation platform that simultaneously measures MxA protein (a viral infection marker) and CRP (a bacterial infection marker) using whole blood. Results are available within 12 minutes, providing a faster and more cost-effective alternative to traditional PCR or blood culture tests. This solution is also recognized as a valuable tool for improving infection management and reducing inappropriate antibiotic prescriptions, which are major contributors to antimicrobial resistance.

During ESCMID Global 2025, Boditech Med also hosted a successful Boditech Med Expert Dinner Meeting, inviting leading infectious disease experts from around the world. The meeting fostered in-depth discussions on the clinical applicability and diagnostic accuracy of Boditech’s products and sparked new opportunities for international collaborative research and partnerships.

Eui-yeol Choi, CEO of Boditech Med, commented:

“Accurate and rapid diagnostics are the cornerstone of global infectious disease response. Through this event, we aim to expand our partnerships across Europe and accelerate our sales growth in the European market.”

• Products classified as Class III high-risk medical devices; approved following local clinical performance evaluations
• Approval for dengue antigen and antibody kits enables detection of primary and secondary infections
• Entry into the Latin American infectious disease diagnostics market expected to drive revenue growth

Boditech Med, a leading provider of point-of-care diagnostics, announced on the 23rd that it has received product approval from Brazil’s National Health Surveillance Agency (ANVISA) for four diagnostic kits, including two for dengue fever and two for latent tuberculosis (LTBI).

The newly approved products include:

• ichroma™ Dengue NS1 Ag (antigen detection)

• ichroma™ Dengue IgG/IgM (antibody detection)

• ichroma™ IGRA-TB and AFIAS IGRA-TB for latent tuberculosis detection

These products have been classified as Class III high-risk medical devices under Brazilian regulations. In particular, the dengue diagnostic kits underwent local clinical performance evaluation as part of the approval process.

Dengue fever has emerged as a major global infectious disease, spreading across Asia, Latin America, and Africa due to climate change and urbanization, which have expanded mosquito habitats. According to the World Health Organization (WHO), more than 14 million cases were officially reported worldwide in 2024—over double the record-setting 2023 total. Brazil alone accounted for over 10 million cases, representing more than 70% of the global total. Unofficial estimates suggest that the actual global number of infections ranges between 100 million and 400 million annually.

While primary dengue infections may present mild symptoms such as fever, headache, and rash, secondary infections can trigger severe complications due to an excessive immune response. For this reason, a dual diagnostic approach using both antigen (NS1) and antibody (IgG/IgM) tests is clinically important. With this ANVISA approval, Boditech Med is now equipped with a complete diagnostic platform capable of differentiating between primary and secondary dengue infections.

Latent tuberculosis infection (LTBI) refers to a state where individuals are infected with Mycobacterium tuberculosis but do not exhibit symptoms or transmit the disease. However, 5–10% of LTBI carriers eventually develop active tuberculosis. According to WHO, over 10 million people contract tuberculosis each year, and approximately 25% of the global population is estimated to be latently infected. Brazil is one of the WHO-designated high-burden TB countries, with over 70,000 new cases reported annually.

Boditech Med’s IGRA-based diagnostic kits, which utilize the Interferon-Gamma Release Assay method, offer a fast and convenient solution for identifying LTBI. These tools are expected to play a critical role in enhancing early detection and preventing the progression to active tuberculosis, particularly in high-risk countries like Brazil.

Eui-yeol Choi, CEO of Boditech Med, stated:

“Brazil is a key player in the Latin American POCT market, and this approval represents a significant step in supporting the country’s efforts to combat both tuberculosis and dengue fever. Meeting ANVISA’s rigorous regulatory standards also reinforces confidence in our products and positions us for meaningful revenue growth in Brazil and the wider Latin American market.”

• New factory established in Jhajjar, India to enhance price competitiveness through local production
• Targets $75 million (approx. 100 billion KRW) in sales from the Indian market; aims to serve as a strategic hub for South Asia and the Middle East
• Pilot production underway, with full-scale manufacturing to begin in Q3 for faster and more cost-effective supply

Boditech Med, a global leader in point-of-care diagnostics, announced on the 7th that it held a successful completion ceremony for its new manufacturing facility located in Jhajjar, India. The new plant is a key part of the company’s strategy to strengthen its presence in the Indian, South Asian, and Middle Eastern markets through local production and enhanced cost competitiveness.

The event was attended by Boditech Med CEO Eui-yeol Choi, Sung-ho Lee, Ambassador of the Republic of Korea to India, local government officials, key partners, and regional leaders.

The Jhajjar facility spans 10,032 square meters (approx. 3,035 pyeong) and will initially focus on the production of high-demand diagnostic kits, including TSH, T3, T4 (thyroid function) and HbA1c (glycated hemoglobin). Production is planned to gradually expand to include a wider range of ichroma™ diagnostic kits.

Currently, pilot production is underway for four diagnostic products, and local manufacturing approvals are expected to be completed by the first half of this year. Full-scale mass production and sales are scheduled to begin in Q3 2025, which is expected to reduce production costs and logistics expenses while enabling faster product supply across the region.

Since entering the Indian market in 2015, Boditech Med has recorded an average annual growth rate of 34%, with 2024 sales reaching $9 million (approx. 12 billion KRW). With the new facility as a foundation, the company plans to further accelerate growth and aims to achieve $75 million (approx. 100 billion KRW) in annual sales and over 5% market share in India by 2030.

Eui-yeol Choi, CEO of Boditech Med, stated,

“India, now the world’s most populous country, is experiencing a rapid surge in demand for point-of-care diagnostics. The primary objective of the new plant is to increase our market share in India, while gradually scaling production to establish it as a strategic base for broader expansion into South Asia and the Middle East.”

He added,

“In the mid- to long-term, our headquarters in Chuncheon will focus on the production of automated AFIAS diagnostic solutions, while ichroma™ products will be manufactured across both domestic and overseas production bases.”